<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26481" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Oxaliplatin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Devanabanda</surname>
            <given-names>Bhavana</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kasi</surname>
            <given-names>Anup</given-names>
          </name>
          <aff>University of Kansas</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bhavana Devanabanda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anup Kasi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26481.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Oxaliplatin is a medication used to manage and treat metastatic colorectal cancer. It is a member of the platinum-based chemotherapeutic class of drugs and is indicated in the adjunctive treatment of stage III colorectal cancer after resection of the primary tumor and for the treatment of metastatic colorectal cancer. It is FDA-approved in combination with infusional 5-fluorouracil and leucovorin. This activity reviews the indications, actions, and contraindications for oxaliplatin as a valuable agent in treating colorectal cancer and will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interaction) pertinent for members of the healthcare team in the treatment of patients with metastatic colorectal cancer and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of oxaliplatin.</p></list-item><list-item><p>Describe the potential adverse effects of oxaliplatin.</p></list-item><list-item><p>Review the appropriate monitoring for patients receiving therapy with oxaliplatin.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to advance oxaliplatin and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26481&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26481">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26481.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Oxaliplatin is an FDA-approved platinum-based antineoplastic medication.<xref ref-type="bibr" rid="article-26481.r1">[1]</xref>&#x000a0;It is indicated in the adjunctive treatment of stage III colorectal cancer after resection of the primary tumor and for the treatment of metastatic colorectal cancer.<xref ref-type="bibr" rid="article-26481.r1">[1]</xref><xref ref-type="bibr" rid="article-26481.r2">[2]</xref>&#x000a0;It is FDA-approved in combination with infusional 5-fluorouracil and leucovorin in a regimen known as FOLFOX.<xref ref-type="bibr" rid="article-26481.r1">[1]</xref></p>
        <p>In the pediatric population, oxaliplatin is used for treating refractory or relapsed solid tumors in combination with etoposide or ifosfamide or gemcitabine or irinotecan or fluorouracil, and leucovorin.<xref ref-type="bibr" rid="article-26481.r3">[3]</xref><xref ref-type="bibr" rid="article-26481.r4">[4]</xref><xref ref-type="bibr" rid="article-26481.r5">[5]</xref><xref ref-type="bibr" rid="article-26481.r6">[6]</xref><xref ref-type="bibr" rid="article-26481.r7">[7]</xref>&#x000a0;Oxaliplatin is also used to treat refractory or relapsed neuroblastoma in combination with doxorubicin.<xref ref-type="bibr" rid="article-26481.r8">[8]</xref><xref ref-type="bibr" rid="article-26481.r9">[9]</xref></p>
        <p>The following are the off-label indications for oxaliplatin:</p>
        <list list-type="bullet">
          <list-item>
            <p>Advanced biliary adenocarcinoma in combination with capecitabine (a regimen known as CAPOX) or gemcitabine.<xref ref-type="bibr" rid="article-26481.r10">[10]</xref><xref ref-type="bibr" rid="article-26481.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Fludarabine refractory chronic lymphocytic leukemia in combination with fludarabine, cytarabine, and rituximab.<xref ref-type="bibr" rid="article-26481.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Esophageal and gastric cancers in combination with epirubicin or capecitabine or docetaxel, leucovorin, and fluorouracil.<xref ref-type="bibr" rid="article-26481.r13">[13]</xref><xref ref-type="bibr" rid="article-26481.r14">[14]</xref><xref ref-type="bibr" rid="article-26481.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Refractory neuroendocrine tumors in combination with capecitabine.<xref ref-type="bibr" rid="article-26481.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Refractory or relapsed non-Hodgkin lymphoma in combination with gemcitabine and rituximab.<xref ref-type="bibr" rid="article-26481.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Advanced ovarian cancer.<xref ref-type="bibr" rid="article-26481.r18">[18]</xref>[</p>
          </list-item>
          <list-item>
            <p>Advanced pancreatic cancer in combination with capecitabine or fluorouracil, leucovorin, and irinotecan.<xref ref-type="bibr" rid="article-26481.r19">[19]</xref><xref ref-type="bibr" rid="article-26481.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Refractory testicular cancer in combination with gemcitabine and paclitaxel.<xref ref-type="bibr" rid="article-26481.r21">[21]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26481.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Oxaliplatin is an alkylating agent and has non-cell cycle-specific cytotoxicity.<xref ref-type="bibr" rid="article-26481.r1">[1]</xref>&#x000a0;The platinum complex in the drug binds to DNA and forms cross-links.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref>&#x000a0;The cross-links inhibit DNA replication, transcription, and arrest of the cell cycle, resulting in cell death.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref>&#x000a0;It works synergistically with fluoropyrimidines such as 5-fluorouracil.<xref ref-type="bibr" rid="article-26481.r1">[1]</xref>&#x000a0;Oxaliplatin effectively treats fast-growing tumors like those in the gastrointestinal system, with a high cell turnover rate.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref></p>
        <p>The pharmacokinetics of unbound platinum in plasma&#x000a0;following oxaliplatin administration were triphasic,&#x000a0;demonstrating a short initial distribution phase&#x000a0;followed by a prolonged terminal elimination phase. Oxaliplatin&#x000a0;is subject to rapid and extensive nonenzymatic biotransformation and is not metabolized by the CYP450&#x000a0;enzyme system.<xref ref-type="bibr" rid="article-26481.r23">[23]</xref> Oxaliplatin half-life varies significantly depending on the resource consulted and the method used to determine half-life.<xref ref-type="bibr" rid="article-26481.r24">[24]</xref> It is excreted in the&#x000a0;urine (approximately 50%) and the feces (2%).</p>
        <p>As monotherapy, oxaliplatin only demonstrates modest antineoplastic activity against advanced colorectal cancer, but it is effective in combination therapy.<xref ref-type="bibr" rid="article-26481.r25">[25]</xref></p>
      </sec>
      <sec id="article-26481.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Oxaliplatin administration is via intravenous infusion (IV) over two hours.<xref ref-type="bibr" rid="article-26481.r26">[26]</xref>&#x000a0;In&#x000a0;cases of acute toxicity, the administration is extended to 6 hours.<xref ref-type="bibr" rid="article-26481.r26">[26]</xref>&#x000a0;The recommended infusion rate is 1mg/m^2/minute or 85 mg/m^2 dose over 85 minutes every two weeks.<xref ref-type="bibr" rid="article-26481.r26">[26]</xref>&#x000a0;Oxaliplatin is moderately emetogenic.<xref ref-type="bibr" rid="article-26481.r27">[27]</xref>&#x000a0;To prevent chemotherapy-induced nausea and vomiting (CINV), pretreatment with antiemetics is strongly recommended.<xref ref-type="bibr" rid="article-26481.r27">[27]</xref></p>
        <p>Before administration, ensure proper needle and catheter placement to prevent extravasation and flush the infusion line with D5W.<xref ref-type="bibr" rid="article-26481.r28">[28]</xref>&#x000a0;It is common for patients to have vascular pain near the site of IV infusion; pretreatment with fast-acting oxycodone is a recommendation.<xref ref-type="bibr" rid="article-26481.r29">[29]</xref>&#x000a0;Monitor the IV site for irritation, redness, pain, and swelling.<xref ref-type="bibr" rid="article-26481.r29">[29]</xref>&#x000a0;In the event of extravasation, immediately discontinue treatment, remove the infusion line, aspirate the solution, do not flush, elevate the site&#x000a0;and place a warm compress over the infusion site;&#x000a0;a cold compress is contraindicated as it can cause acute neurological symptoms.<xref ref-type="bibr" rid="article-26481.r28">[28]</xref></p>
        <p>Adult administration regimens are as follows: (consult facility protocols and manufacturer's package insert for dosing, pre-medications, and toxicity-based dose adjustments)</p>
        <list list-type="bullet">
          <list-item>
            <p>As an adjuvant in stage III colon cancer: 85 mg/m^2 IV for a single dose on day one of a 14-day cycle, used with 5-FU and leucovorin. Administer 12 cycles.</p>
          </list-item>
          <list-item>
            <p>Advanced colorectal cancer:&#x000a0;85 mg/m^2 IV for a single dose on day one of a 14-day cycle, used with 5-FU and leucovorin.</p>
          </list-item>
        </list>
        <p>There is no pediatric indication for oxaliplatin.</p>
        <p>Dosing in patients with renal insufficiency (creatinine clearance less than 30): Start 65 mg/m^2 for one dose on day one of a 14-day cycle. Hepatic dosing is undefined.</p>
      </sec>
      <sec id="article-26481.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse drug effects reported with oxaliplatin monotherapy are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Systemic: fever, fatigue, nausea, emesis, weakness<xref ref-type="bibr" rid="article-26481.r30">[30]</xref><xref ref-type="bibr" rid="article-26481.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Nervous system: peripheral sensory neuropathy, pain, headache, insomnia<xref ref-type="bibr" rid="article-26481.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>Gastrointestinal system: diarrhea, abdominal pain, constipation, anorexia, stomatitis<xref ref-type="bibr" rid="article-26481.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Hepatic: elevated serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin<xref ref-type="bibr" rid="article-26481.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Hematologic and oncologic: anemia, thrombocytopenia, leukopenia<xref ref-type="bibr" rid="article-26481.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Musculoskeletal: back pain<xref ref-type="bibr" rid="article-26481.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p>Respiratory system: dyspnea, cough<xref ref-type="bibr" rid="article-26481.r30">[30]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26481.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Oxaliplatin is contraindicated in patients who have/are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Platinum hypersensitivity anaphylaxis<xref ref-type="bibr" rid="article-26481.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Posterior reversible encephalopathy syndrome<xref ref-type="bibr" rid="article-26481.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Grade 3 or 4 peripheral sensory neuropathy<xref ref-type="bibr" rid="article-26481.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>Severe renal impairment<xref ref-type="bibr" rid="article-26481.r35">[35]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic lung disease<xref ref-type="bibr" rid="article-26481.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Rhabdomyolysis<xref ref-type="bibr" rid="article-26481.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Sepsis<xref ref-type="bibr" rid="article-26481.r38">[38]</xref></p>
          </list-item>
          <list-item>
            <p>Pregnant or intending to get pregnant<xref ref-type="bibr" rid="article-26481.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p>Breastfeeding<xref ref-type="bibr" rid="article-26481.r39">[39]</xref></p>
          </list-item>
        </list>
        <p>Use in the first trimester should be avoided due to high teratogenicity and embryo&#x000a0;or fetal death. Females of reproductive potential should have a pregnancy test prior to initiating therapy and must use appropriate contraception during treatment and for nine months following discontinuation of oxaliplatin. Male patients should continue contraception for six months following treatment cessation.<xref ref-type="bibr" rid="article-26481.r40">[40]</xref>&#x000a0;Patients should avoid breastfeeding during treatment and for three months following treatment termination. While there is no data available to assess infant harm in breastfeeding, excretion into breast milk is possible based on the drug's properties. There is no data on oxaliplatin's effect on milk production.</p>
      </sec>
      <sec id="article-26481.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients on oxaliplatin therapy must periodically have blood and urine work up to assess complete blood count with differential, basic metabolic panel, liver function tests, renal function tests, and electrocardiogram (ECG) for QT prolongation.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref>&#x000a0;It is essential to do a pregnancy test on women of reproductive age before initiating treatment.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref></p>
        <p>Oxaliplatin has a narrow therapeutic index, which most commonly affects the hematopoietic and nervous systems and has gastrointestinal side effects.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref>&#x000a0;Periodic neurological exams are a recommendation to assess for acute or chronic oxaliplatin-induced peripheral neuropathy<xref ref-type="bibr" rid="article-26481.r22">[22]</xref></p>
        <p>Drug interactions: Oxaliplatin requires close monitoring when administered with other drugs as it can enhance the adverse/toxic effects or diminish the therapeutic effects. The following drug interactions are important to consider:</p>
        <list list-type="bullet">
          <list-item>
            <p>Baricitinib</p>
          </list-item>
          <list-item>
            <p>Disease-modifying anti-rheumatic drugs (DMARDs)</p>
          </list-item>
          <list-item>
            <p>Chloramphenicol</p>
          </list-item>
          <list-item>
            <p>Cladribine</p>
          </list-item>
          <list-item>
            <p>Clozapine</p>
          </list-item>
          <list-item>
            <p>Deferiprone</p>
          </list-item>
          <list-item>
            <p>Denosumab</p>
          </list-item>
          <list-item>
            <p>Dipyrone</p>
          </list-item>
          <list-item>
            <p>Echinacea</p>
          </list-item>
          <list-item>
            <p>Erdafitinib</p>
          </list-item>
          <list-item>
            <p>Fingolimod</p>
          </list-item>
          <list-item>
            <p>Fosphenytoin-phenytoin</p>
          </list-item>
          <list-item>
            <p>Haloperidol</p>
          </list-item>
          <list-item>
            <p>Leflunomide</p>
          </list-item>
          <list-item>
            <p>Lenograstim</p>
          </list-item>
          <list-item>
            <p>Lipegfilgrastim</p>
          </list-item>
          <list-item>
            <p>Mesalamine</p>
          </list-item>
          <list-item>
            <p>Natalizumab</p>
          </list-item>
          <list-item>
            <p>Nivolumab</p>
          </list-item>
          <list-item>
            <p>Ocrelizumab</p>
          </list-item>
          <list-item>
            <p>Palifermin</p>
          </list-item>
          <list-item>
            <p>Pidotimod</p>
          </list-item>
          <list-item>
            <p>Pimecrolimus</p>
          </list-item>
          <list-item>
            <p>Promazine</p>
          </list-item>
          <list-item>
            <p>QT-prolonging agents</p>
          </list-item>
          <list-item>
            <p>Roflumilast</p>
          </list-item>
          <list-item>
            <p>Siponimod</p>
          </list-item>
          <list-item>
            <p>Sipuleucel-T&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Tacrolimus</p>
          </list-item>
          <list-item>
            <p>Tafenoquine</p>
          </list-item>
          <list-item>
            <p>Taxane derivatives</p>
          </list-item>
          <list-item>
            <p>Tertomotide</p>
          </list-item>
          <list-item>
            <p>Tofacitinib</p>
          </list-item>
          <list-item>
            <p>Topotecan</p>
          </list-item>
          <list-item>
            <p>Upadacitinib</p>
          </list-item>
          <list-item>
            <p>Vaccines</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26481.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>No known antidote exists for oxaliplatin overdose. Oxaliplatin has dose-dependent toxicity on the hematopoietic system. It causes myelosuppression, anemia, and thrombocytopenia.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref>&#x000a0;In rare cases with repeated oxaliplatin treatment, hypersensitivity reactions, hemolytic anemia, and secondary immune thrombocytopenia can occur.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref>&#x000a0;The therapy is discontinuation and symptomatic management.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref></p>
        <p>Oxaliplatin has dose-limiting toxicity on the nervous system.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref> It can cause acute or chronic peripheral neuropathy.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref> Acute oxaliplatin-induced peripheral neuropathy presents with paresthesia, dysesthesias, or allodynia, usually around the mouth and throat during or after the treatment.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref> Exposure to cold can also trigger these symptoms.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref> The symptoms resolve within a few hours to days following discontinuation.<xref ref-type="bibr" rid="article-26481.r34">[34]</xref>&#x000a0;Additional precautions are possible by prolonging the infusion time from two hours to six hours.<xref ref-type="bibr" rid="article-26481.r34">[34]</xref></p>
        <p>Repeated oxaliplatin treatment can result in chronic peripheral neuropathy.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref> It manifests in the distal extremities with paresthesia, hypoesthesia, dysesthesia, and decreased proprioception.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref> It is seen in 10% of patients who receive a cumulative dose of 780 mg/m^2 (9 doses of 85mg/m^2) and 50% of patients who receive a cumulative dose of 1170 mg/m^2 (13 doses).<xref ref-type="bibr" rid="article-26481.r34">[34]</xref> One study has shown a decreased incidence of neurotoxicity in patients receiving supplemental infusions of calcium and magnesium on the day of oxaliplatin administration.<xref ref-type="bibr" rid="article-26481.r34">[34]</xref>&#x000a0;There is preliminary and conflicting data on the use of oral n-acetylcysteine, xaliproden, gabapentin, carbamazepine, amifostine, and glutathione in the prevention or amelioration of oxaliplatin-induced neuropathy.<xref ref-type="bibr" rid="article-26481.r34">[34]</xref></p>
      </sec>
      <sec id="article-26481.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Interprofessional&#x000a0;treatment teams consisting of clinicians (MDs, DOs, NPs, and PAs), oncology specialists, nurses, laboratory technologists, pharmacists, and clinicians in different specialties need to be knowledgeable&#x000a0;regarding the use and potential adverse events of oxaliplatin. This interprofessional team approach ensures proper administration, management, monitoring, and limitation of the adverse effects. When a patient is on a chemotherapeutic regimen, it is strongly advised to utilize a board-certified oncology specialty pharmacist&#x000a0;who can examine the treatment regimen (including pre and post medication),&#x000a0;communicate possible drug interactions, and the recommended therapeutic dosage to the clinician.</p>
        <p>The assigned nursing staff must monitor the IV site, be cognizant of the adverse effects of the drug, and relay them to the clinician and/or pharmacist. As with pharmacy, having oncology-certified nurses involved in the pre-and post-administration care, in addition to performing administration, can optimize patient outcomes. These nurses will report to the ordering clinician any issues or concerns they see so remedial action (dose adjustments, additional medication, etc.) can be implemented.</p>
        <p>Lastly, the clinician must have enough information to determine if the patient is a candidate to receive a drug like oxaliplatin&#x000a0;depending on the patient's medical history; here again, consulting with an oncology pharmacist can prove invaluable.</p>
        <p>The interpersonal healthcare team is responsible for the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete blood count, liver function tests, renal function tests, pregnancy test</p>
          </list-item>
          <list-item>
            <p>Proper administration of the drug and monitoring of the IV site</p>
          </list-item>
          <list-item>
            <p>Monitoring toxicity</p>
          </list-item>
          <list-item>
            <p>Monitor the patient for signs and symptoms of CINV, peripheral sensory neuropathy, infection, GI disturbances</p>
          </list-item>
          <list-item>
            <p>Consult with the pharmacist and toxicologist&#x000a0;regarding dosing</p>
          </list-item>
          <list-item>
            <p>Consult with the radiologist, pathologist, and surgeon regarding the spread of cancer</p>
          </list-item>
        </list>
        <p>The prevention and management of oxaliplatin-induced neurotoxicity start with the patient limiting exposure to cold environments, ensuring proper protection, and staying away from cold food and beverages.<xref ref-type="bibr" rid="article-26481.r22">[22]</xref>&#x000a0;One study has shown a decrease in neurotoxicity in patients who received calcium and magnesium infusions before or after oxaliplatin administration.<xref ref-type="bibr" rid="article-26481.r41">[41]</xref>&#x000a0;[Level&#x000a0;2] In addition to changing the dosage, the interprofessional treatment team&#x000a0;may consider supplementing oxaliplatin with&#x000a0;calcium or magnesium in the event of peripheral sensory neuropathy.</p>
        <p>WIth an interprofessional team approach to oxaliplatin therapy, patients stand to achieve the best possible outcomes with this drug while minimizing potential adverse effects. [Level 5]</p>
      </sec>
      <sec id="article-26481.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26481&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26481">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26481/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26481">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26481.s11">
        <title>References</title>
        <ref id="article-26481.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyerhardt</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Systemic therapy for colorectal cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Feb</month>
            <day>03</day>
            <volume>352</volume>
            <issue>5</issue>
            <fpage>476</fpage>
            <page-range>476-87</page-range>
            <pub-id pub-id-type="pmid">15689586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noepel-Duennebacke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hertel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tannapfel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hinke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hegewisch-Becker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reinacher-Schick</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.</article-title>
            <source>Clin Colorectal Cancer</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>e733</fpage>
            <page-range>e733-e739</page-range>
            <pub-id pub-id-type="pmid">30145148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lam</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Furman</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spunt</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ivy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Santana</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>McGregor</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>e13</fpage>
            <page-range>e13-8</page-range>
            <pub-id pub-id-type="pmid">24942022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGregor</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Spunt</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Santana</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laningham</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Ivy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Furman</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Fouladi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.</article-title>
            <source>Cancer</source>
            <year>2009</year>
            <month>Feb</month>
            <day>01</day>
            <volume>115</volume>
            <issue>3</issue>
            <fpage>655</fpage>
            <page-range>655-64</page-range>
            <pub-id pub-id-type="pmid">19117350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geoerger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chisholm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Le Deley</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gentet</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Zwaan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Dias</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jaspan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mc Hugh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Couanet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Devos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Riccardi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cesare</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frappaz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aerts</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vassal</surname>
                <given-names>G</given-names>
              </name>
              <collab>European Consortium Innovative Therapies for Children with Cancer (ITCC)</collab>
            </person-group>
            <article-title>Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.</article-title>
            <source>Eur J Cancer</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>230</fpage>
            <page-range>230-8</page-range>
            <pub-id pub-id-type="pmid">20943374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macy</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Whitlock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hunger</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Boklan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Narendren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Herzog</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arceci</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bagatell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Trippett</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Christians</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Rolla</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ivy</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Gore</surname>
                <given-names>L</given-names>
              </name>
              <collab>Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC)</collab>
            </person-group>
            <article-title>A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>230</fpage>
            <page-range>230-6</page-range>
            <pub-id pub-id-type="pmid">23024067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weinel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grigull</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Linderkamp</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Welte</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Reinhardt</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>344</fpage>
            <page-range>344-9</page-range>
            <pub-id pub-id-type="pmid">21572345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mascarenhas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Malogolowkin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Armenian</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Sposto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Venkatramani</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>60</volume>
            <issue>7</issue>
            <fpage>1103</fpage>
            <page-range>1103-7</page-range>
            <pub-id pub-id-type="pmid">23335436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tran</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Marachelian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Venkatramani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jubran</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Mascarenhas</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.</article-title>
            <source>Pediatr Hematol Oncol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-31</page-range>
            <pub-id pub-id-type="pmid">25551355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andr&#x000e9;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Boni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mounedji-Boudiaf</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tabernero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hickish</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Topham</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zaninelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clingan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bridgewater</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tabah-Fisch</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>de Gramont</surname>
                <given-names>A</given-names>
              </name>
              <collab>Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators</collab>
            </person-group>
            <article-title>Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Jun</month>
            <day>03</day>
            <volume>350</volume>
            <issue>23</issue>
            <fpage>2343</fpage>
            <page-range>2343-51</page-range>
            <pub-id pub-id-type="pmid">15175436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nehls</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Oettle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Hofheinz</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hass</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Horger</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Koppenh&#x000f6;fer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hochhaus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stieler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trojan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gregor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klump</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.</article-title>
            <source>Br J Cancer</source>
            <year>2008</year>
            <month>Jan</month>
            <day>29</day>
            <volume>98</volume>
            <issue>2</issue>
            <fpage>309</fpage>
            <page-range>309-15</page-range>
            <pub-id pub-id-type="pmid">18182984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsimberidou</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wierda</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Plunkett</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kurzrock</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferrajoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ravandi-Kashani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garcia-Manero</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Estrov</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kipps</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Fiorentino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>Jan</month>
            <day>10</day>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>196</fpage>
            <page-range>196-203</page-range>
            <pub-id pub-id-type="pmid">18182662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunningham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Starling</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iveson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nicolson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coxon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Middleton</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oates</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>AR</given-names>
              </name>
              <collab>Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom</collab>
            </person-group>
            <article-title>Capecitabine and oxaliplatin for advanced esophagogastric cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Jan</month>
            <day>03</day>
            <volume>358</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-46</page-range>
            <pub-id pub-id-type="pmid">18172173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Batran</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Hofheinz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Homann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rethwisch</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Probst</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stoehlmacher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Mahlberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fritz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seipelt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sievert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pauligk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Atmaca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>J&#x000e4;ger</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.</article-title>
            <source>Ann Oncol</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>11</issue>
            <fpage>1882</fpage>
            <page-range>1882-7</page-range>
            <pub-id pub-id-type="pmid">18669868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conroy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yatagh&#x000e8;ne</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Etienne</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Michel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Senellart</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Raoul</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Mineur</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rives</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mirabel</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lamezec</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Le Pris&#x000e9;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Peiffert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Adenis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer.</article-title>
            <source>Br J Cancer</source>
            <year>2010</year>
            <month>Oct</month>
            <day>26</day>
            <volume>103</volume>
            <issue>9</issue>
            <fpage>1349</fpage>
            <page-range>1349-55</page-range>
            <pub-id pub-id-type="pmid">20940718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bajetta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Catena</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Procopio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Dosso</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bichisao</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martinetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Platania</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verzoni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Formisano</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bajetta</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>637</fpage>
            <page-range>637-42</page-range>
            <pub-id pub-id-type="pmid">16937105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f3;pez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palacios</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blancas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Navarrete</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perell&#x000f3;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alarc&#x000f3;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study.</article-title>
            <source>Eur J Haematol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>80</volume>
            <issue>2</issue>
            <fpage>127</fpage>
            <page-range>127-32</page-range>
            <pub-id pub-id-type="pmid">18005385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dieras</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bougnoux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Petit</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chollet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Beuzeboc</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Borel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Husseini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Goupil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kerbrat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Misset</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bensma&#x000ef;ne</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tabah-Fisch</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pouillart</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.</article-title>
            <source>Ann Oncol</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>258</fpage>
            <page-range>258-66</page-range>
            <pub-id pub-id-type="pmid">11886003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xiong</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Varadhachary</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Blais</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Abbruzzese</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wolff</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.</article-title>
            <source>Cancer</source>
            <year>2008</year>
            <month>Oct</month>
            <day>15</day>
            <volume>113</volume>
            <issue>8</issue>
            <fpage>2046</fpage>
            <page-range>2046-52</page-range>
            <pub-id pub-id-type="pmid">18756532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conroy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Desseigne</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ychou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bouch&#x000e9;</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Guimbaud</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>B&#x000e9;couarn</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Adenis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raoul</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gourgou-Bourgade</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de la Fouchardi&#x000e8;re</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bennouna</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bachet</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Khemissa-Akouz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>P&#x000e9;r&#x000e9;-Verg&#x000e9;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Delbaldo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Assenat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chauffert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Michel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Montoto-Grillot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ducreux</surname>
                <given-names>M</given-names>
              </name>
              <collab>Groupe Tumeurs Digestives of Unicancer</collab>
              <collab>PRODIGE Intergroup</collab>
            </person-group>
            <article-title>FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>May</month>
            <day>12</day>
            <volume>364</volume>
            <issue>19</issue>
            <fpage>1817</fpage>
            <page-range>1817-25</page-range>
            <pub-id pub-id-type="pmid">21561347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bokemeyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oechsle</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Honecker</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Waller</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hlke</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kollmannsberger</surname>
                <given-names>C</given-names>
              </name>
              <collab>German Testicular Cancer Study Group</collab>
            </person-group>
            <article-title>Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.</article-title>
            <source>Ann Oncol</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>448</fpage>
            <page-range>448-53</page-range>
            <pub-id pub-id-type="pmid">18006893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alcindor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Beauger</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Oxaliplatin: a review in the era of molecularly targeted therapy.</article-title>
            <source>Curr Oncol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-25</page-range>
            <pub-id pub-id-type="pmid">21331278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graham</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lockwood</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Greenslade</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brienza</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bayssas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gamelin</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of oxaliplatin: a critical review.</article-title>
            <source>Clin Cancer Res</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>1205</fpage>
            <page-range>1205-18</page-range>
            <pub-id pub-id-type="pmid">10778943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ehrsson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wallin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yachnin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of oxaliplatin in humans.</article-title>
            <source>Med Oncol</source>
            <year>2002</year>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>261</fpage>
            <page-range>261-5</page-range>
            <pub-id pub-id-type="pmid">12512920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000e9;couarn</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ychou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ducreux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bertheault-Cvitkovic</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Seitz</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Nasca</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Paillot</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Raoul</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Duffour</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fandi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dupont-Andr&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rougier</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.</article-title>
            <source>J Clin Oncol</source>
            <year>1998</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>2739</fpage>
            <page-range>2739-44</page-range>
            <pub-id pub-id-type="pmid">9704726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cercek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Yaeger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Reidy-Lagunes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kemeny</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Stadler</surname>
                <given-names>ZK</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Varghese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saltz</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min.</article-title>
            <source>J Oncol Pract</source>
            <year>2016</year>
            <month>May</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>e548</fpage>
            <page-range>e548-53</page-range>
            <pub-id pub-id-type="pmid">27072569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatakeyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Konno</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Toyoguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shiraishi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>[Effects of Serum Sodium Concentrations on Nausea and Vomiting after Moderately Emetogenic Chemotherapy].</article-title>
            <source>Yakugaku Zasshi</source>
            <year>2018</year>
            <volume>138</volume>
            <issue>8</issue>
            <fpage>1095</fpage>
            <page-range>1095-1101</page-range>
            <pub-id pub-id-type="pmid">30068850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Lemos</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Walisser</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Management of extravasation of oxaliplatin.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>159</fpage>
            <page-range>159-62</page-range>
            <pub-id pub-id-type="pmid">16595069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suga</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Staub</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yonezawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kitade</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Katsura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishizaki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsushita</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for oxaliplatin-induced vascular pain in patients with colorectal cancer and comparison of the efficacy of preventive methods.</article-title>
            <source>J Pharm Health Care Sci</source>
            <year>2018</year>
            <volume>4</volume>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">30094053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khurana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mitsis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kowlgi</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Holle</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Clement</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Atypical presentation of fever as hypersensitivity reaction to oxaliplatin.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>319</fpage>
            <page-range>319-24</page-range>
            <pub-id pub-id-type="pmid">25361599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saif</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Reardon</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Management of oxaliplatin-induced peripheral neuropathy.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>1</volume>
            <issue>4</issue>
            <fpage>249</fpage>
            <page-range>249-58</page-range>
            <pub-id pub-id-type="pmid">18360567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurk</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Peeters</surname>
                <given-names>PHM</given-names>
              </name>
              <name>
                <surname>Dorresteijn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Jourdan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuijf</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Punt</surname>
                <given-names>CJA</given-names>
              </name>
              <name>
                <surname>Koopman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients.</article-title>
            <source>J Cachexia Sarcopenia Muscle</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>909</fpage>
            <page-range>909-919</page-range>
            <pub-id pub-id-type="pmid">30144305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharief</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin.</article-title>
            <source>Clin Colorectal Cancer</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>163</fpage>
            <page-range>163-5</page-range>
            <pub-id pub-id-type="pmid">19632931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cersosimo</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Oxaliplatin-associated neuropathy: a review.</article-title>
            <source>Ann Pharmacother</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>128</fpage>
            <page-range>128-35</page-range>
            <pub-id pub-id-type="pmid">15590869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takimoto</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Remick</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ramanathan</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Doroshow</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mulkerin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lockwood</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Ivy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Egorin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Greenslade</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goetz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grem</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.</article-title>
            <source>Semin Oncol</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>4 Suppl 15</issue>
            <fpage>20</fpage>
            <page-range>20-5</page-range>
            <pub-id pub-id-type="pmid">14523791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ryu</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>DY</given-names>
              </name>
            </person-group>
            <article-title>Oxaliplatin-induced Pulmonary Fibrosis: Two Case Reports.</article-title>
            <source>J Korean Soc Coloproctol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>266</fpage>
            <page-range>266-9</page-range>
            <pub-id pub-id-type="pmid">22102978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pissarra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malheiro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matos</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Pl&#x000e1;cido</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>Severe rhabdomyolysis related to oxaliplatin adjuvant therapy for colorectal cancer.</article-title>
            <source>BMJ Case Rep</source>
            <year>2019</year>
            <month>Apr</month>
            <day>16</day>
            <volume>12</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">30996068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janinis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Papakostas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Samelis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Skarlos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Papagianopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fountzilas</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.</article-title>
            <source>Ann Oncol</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-7</page-range>
            <pub-id pub-id-type="pmid">10761750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rogers</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Dasari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges.</article-title>
            <source>Oncologist</source>
            <year>2016</year>
            <month>May</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>563</fpage>
            <page-range>563-70</page-range>
            <pub-id pub-id-type="pmid">27000464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r40">
          <label>40</label>
          <element-citation publication-type="book">
            <chapter-title>Oxaliplatin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">33226756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26481.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gamelin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boisdron-Celle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Delva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gu&#x000e9;rin-Meyer</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ifrah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Morel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gamelin</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.</article-title>
            <source>Clin Cancer Res</source>
            <year>2004</year>
            <month>Jun</month>
            <day>15</day>
            <volume>10</volume>
            <issue>12 Pt 1</issue>
            <fpage>4055</fpage>
            <page-range>4055-61</page-range>
            <pub-id pub-id-type="pmid">15217938</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
